REVOLADE

This brand name is authorized in Australia, Austria, Brazil, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug REVOLADE contains one active pharmaceutical ingredient (API):

1	Eltrombopag UNII 4U07F515LG - ELTROMBOPAG OLAMINE
	Endogenous thrombopoietin (TPO) is the main cytokine involved in regulation of megakaryopoiesis and platelet production, and is the endogenous ligand for the TPO-R. Eltrombopag interacts with the transmembrane domain of the human TPO-R and initiates signalling cascades similar but not identical to that of endogenous thrombopoietin (TPO), inducing proliferation and differentiation from bone marrow progenitor cells.
	Read more about Eltrombopag

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
REVOLADE Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BX05	Eltrombopag	B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics
Discover more medicines within B02BX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	5825N, 5826P, 5827Q, 5828R
BR	Câmara de Regulação do Mercado de Medicamentos	526517050089317, 526517050089417
CA	Health Products and Food Branch	02361825, 02361833
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	2671-MEE-0417, 3035-MEE-0917
EE	Ravimiamet	1461990, 1462003, 1462014, 1462025, 1462036, 1462047, 1696158, 1696169, 1696170, 1715396, 1715408, 1715419, 1715442
ES	Centro de información online de medicamentos de la AEMPS	10612002, 10612005, 110612013
FI	Lääkealan turvallisuus- ja kehittämiskeskus	048177, 048189, 428609, 494314
FR	Base de données publique des médicaments	60757264, 61736230, 61951699, 67675236
GB	Medicines & Healthcare Products Regulatory Agency	170753, 170756, 347006, 394262
HK	Department of Health Drug Office	62055, 62056
IE	Health Products Regulatory Authority	88313, 88314
IL	מִשְׂרַד הַבְּרִיאוּת	6326, 6328
IT	Agenzia del Farmaco	039827011, 039827023, 039827035, 039827047, 039827050, 039827062, 039827074, 039827086, 039827098, 039827100, 039827112, 039827124, 039827136
JP	医薬品医療機器総合機構	3999028F1025, 3999028F2021
LT	Valstybinė vaistų kontrolės tarnyba	1053805, 1053806, 1053807, 1053808, 1053809, 1053810, 1072070, 1072071, 1072072, 1080020, 1080021, 1080022, 1080023
NL	Z-Index G-Standaard, PRK	108219, 93963, 93971
NZ	Medicines and Medical Devices Safety Authority	14582, 14583, 16164
PL	Rejestru Produktów Leczniczych	100219971, 100219988, 100245141, 100369908, 100369914
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64445001, W64445002, W64445003, W64446001, W64446002, W64446003
SG	Health Sciences Authority	13909P, 13910P
TN	Direction de la Pharmacie et du Médicament	20833051H, 80833052H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699504092103, 8699504092110, 8699504093087
ZA	Health Products Regulatory Authority	44/26/0548, 44/26/0549